Key aspects of medication adherence to oral anticancer drugs: A literature review

At least 25% of the anticancer drugs are intended for oral use, while the creation and rapid introduction of oral drugs into clinical practice is constantly growing. Between 2006 and 2021, 80 oral forms of anticancer drugs were approved. It has been shown that patients prefer oral therapy to intravenous therapy if such a replacement is possible with equal efficacy and toxicity of the drugs. This once again emphasizes that the issue of adherence to treatment with oral forms is open and relevant for study. Currently, adherence, as the main factor in achieving the best clinical outcome, has been studied from different perspectives. However, there are no structured data globally, and, accordingly, evidence-based and specific recommendations in the absence of adherence. The review includes data from studies performed over the past 10 years, studying the adherence of patients to treatment with oral anticancer drugs. The data sources for the review were the Medline, Embase, and Scopus databases. Literature analysis showed that the most important aspects in the field of adherence to treatment with oral anticancer drugs include the level of patient adherence to treatment, factors affecting non-compliance, correlation of treatment adherence and clinical outcomes in malignant neoplasms. At the same time, the article considers the impact of non-compliance on the health care system as a whole. The most reliable and up-to-date data in the study area were examined to subsequently identify measures aimed at achieving the best practice in the organization of healthcare for patients with malignant neoplasms. The research results demonstrate the variability and heterogeneity of data, the lack of unified methodological approaches. In turn, this prevents the formation of objective and reliable conclusions about adherence. To make rational strategic decisions on monitoring adherence to treatment, it is necessary to initiate large-scale studies, adopt uniform standard procedures and recommendations for assessing adherence.

1. Zaugg V, Korb-Savoldelli V, Durieux P, Sabatier B. Providing physicians with feedback on medication adherence for people with chronic diseases taking long-term medication. Cochrane Database Syst Rev. 2018;1:CD012042. https://doi.org/10.1002/14651858.CD012042.pub2.

2. Lukina IuV, Kutishenko NP, Martsevich SIu, Shepel RN, Drapkina OM. Methodological recommendations: “Adherence to drug therapy in patients with chronic non-communicable diseases. Addressing the problem in a number of clinical situations”. Profilakticheskaya Meditsina. 2020;23(3):42–60. (In Russ.) Available at: https://www.mediasphera.ru/issues/profilakticheskaya-meditsina/2020/3/downloads/ru/1230549482020032042.

3. Dombrovskiy VS, Omelyanovskiy VV. Study of the adherence to treatment: evaluation criteria and terminology. Medical Technologies. Assessment and Choice. 2015;(2):16–23. (In Russ.) Available at: https://www.mediasphera.ru/issues/meditsinskie-tekhnologii-otsenka-i-vybor/2015/2.

4. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–47. https://doi.org/10.1111/j.1524-4733.2007.00213.x.

5. Lasala R, Santoleri F, Romagnoli A, Abrate P, Musicco F, Costantini A. Medication adherence reporting in pivotal clinical trials: overview of oral oncological drugs. Eur J Hosp Pharm Sci Pract. 2023;30(6):328–332. https://doi.org/10.1136/ejhpharm-2021-002998.

6. Pantziarka P, Capistrano IR, De Potter A, Vandeborne L, Bouche G. An Open Access Database of Licensed Cancer Drugs. Front Pharmacol. 2021;12:627574. https://doi.org/10.3389/fphar.2021.627574.

7. Mueller-Schoell A, Groenland SL, Scherf-Clavel O, van Dyk M, Huisinga W, Michelet R et al. Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur J Clin Pharmacol. 2021;77(4):441–464. https://doi.org/10.1007/s00228-020-03014-8.

8. Levit LA, Arora S, Kluetz PG, Magnuson A, Rahman A, Harvey RD. Call to Action for Improving Oral Anticancer Agent Adherence. J Clin Oncol. 2022;40(10):1036–1040. https://doi.org/10.1200/JCO.21.02529.

9. List of Vital and Essential Medicines, 2021. Malignant Tumours. 2021;11(3s2-1):598–608. (In Russ.) Available at: https://www.malignanttumors.org/jour/article/view/884.

10. Schlichtig K, Dürr P, Dörje F, Fromm MF. New Oral Anti-Cancer Drugs and Medication Safety. Dtsch Arztebl Int. 2019;116:775–782. https://doi.org/10.3238/arztebl.2019.0775.

11. Eek D, Krohe M, Mazar I, Horsfield A, Pompilus F, Friebe R et al. Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Prefer Adherence. 2016;10:1609–1621. https://doi.org/10.2147/PPA.S106629.

12. Twelves C, Gollins S, Grieve R, Samuel L. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/ leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol. 2006;17:239–245. https://doi.org/10.1093/annonc/mdj023.

13. Ciruelos EM, Díaz MN, Isla MD, López R, Bernabé R, González E et al. Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer. Eur J Cancer Care (Engl). 2019;28:e13164. https://doi.org/10.1111/ecc.13164.

14. Dazzi C, Gamboni A, Delmonte A, Rosetti F, Verlicchi A, Papi M et al. Randomized cross-over study of patient preference for oral or intravenous vinorelbine in the treatment of advanced NSCLC: A phase IV study. J Clin Oncol. 2017;35:e20676-e20676. https://doi.org/10.1200/JCO.2017.35.15_suppl.e20676.

15. Chekerov R, Harter P, Fuxius S, Hanker LC, Woelber L, Müller L et al. Preference of elderly patients’ to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial. Gynecol Oncol Res Pract. 2017;4:6. https://doi.org/10.1186/s40661-017-0040-2.

16. Rega ML, Calabrese C, Tortorella P, de Waure C, Damiani G. The Adherence’s indicators of cancer patients to oral chemotherapy. A sistematic literature review. Prof Inferm. 2018;71:67–78. https://doi.org/10.7429/pi.2018.712067.

17. Hartman L, Lems WF, Boers M. Outcome measures for adherence data from a medication event monitoring system: A literature review. J Clin Pharm Ther. 2019;44:1–5. https://doi.org/10.1111/jcpt.12757.

18. Puspitasari AW, Kristina SA, Prabandari YS. Overview of Adherence and Influencing Factors to Capecitabine In Cancer Patients: Systematic Review. Int J Pharm Res. 2021;13. https://doi.org/10.31838/ijpr/2021.13.01.476.

19. Chen Y, Wu X, Xian X, Zhang Y, Gong N, Qin H et al. Adherence to oral chemotherapy among colorectal cancer patients: A longitudinal study. Eur J Oncol Nurs. 2020;48:101822. https://doi.org/10.1016/j.ejon.2020.101822.

20. Kawakami K, Nakamoto E, Yokokawa T, Sugita K, Mae Y, Hagino A et al. Patients’ self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis. Patient Prefer Adherence. 2015;9:561–567. https://doi.org/10.2147/PPA.S80327.

21. Greer JA, Amoyal N, Nisotel L, Fishbein JN, MacDonald J, Stagl J et al. A Systematic Review of Adherence to Oral Antineoplastic Therapies. Oncologist. 2016;21:354–376. https://doi.org/10.1634/theoncologist.2015-0405.

22. Nguyen T-M-U, La Caze A, Cottrell N. What are validated self-report adherence scales really measuring?: a systematic review. Br J Clin Pharmacol. 2014;77:427–445. https://doi.org/10.1111/bcp.12194.

23. Gast A, Mathes T. Medication adherence influencing factors – an (updated) overview of systematic reviews. Syst Rev. 2019;8:112. https://doi.org/10.1186/s13643-019-1014-8.

24. Iacorossi L, Gambalunga F, De Domenico R, Serra V, Marzo C, Carlini P. Qualitative study of patients with metastatic prostate cancer to adherence of hormone therapy. Eur J Oncol Nurs. 2019;38:8–12. https://doi.org/10.1016/j.ejon.2018.11.004.

25. Pilon D, LaMori J, Rossi C, Durkin M, Ghelerter I, Ke X et al. Medication adherence among patients with advanced prostate cancer using oral therapies. Future Oncol. 2022;18:231–243. https://doi.org/10.2217/fon-2021-0992.

26. Wells KJ, Pan TM, Vázquez-Otero C, Ung D, Ustjanauskas AE, Muñoz D et al. Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study. Support Care Cancer. 2016;24:4123–30. https://doi.org/10.1007/s00520-016-3229-8.

27. Verbrugghe M, Verhaeghe S, Decoene E, De Baere S, Vandendorpe B, Van Hecke A. Factors influencing the process of medication (non-)adherence and (non-)persistence in breast cancer patients with adjuvant antihormonal therapy: a qualitative study. Eur J Cancer Care (Engl). 2017;26(2):e12339. https://doi.org/10.1111/ecc.12339.

28. Nizet P, Touchefeu Y, Pecout S, Cauchin E, Beaudouin E, Mayol S et al. Exploring the factors influencing adherence to oral anticancer drugs in patients with digestive cancer: a qualitative study. Support Care Cancer. 2022;30:2591–2604. https://doi.org/10.1007/s00520-021-06663-2.

29. Elston Lafata J, Nguyen B, Staresinic C, Johnson M, Gratie D, Muluneh B. Interpersonal communication-, education- and counselling-based interventions to support adherence to oral anticancer therapy: a systematic review. J Oncol Pharm Pract. 2023;29(2):358–369. https://doi.org/10.1177/10781552211073576.

30. Kaptein AA, Schoones JW, van der Meer PB, Matsuda A, Murray M, Heimans L et al. Psychosocial determinants of adherence with oral anticancer treatment: “we don’t need no education”. Acta Oncol. 2021;60:87–95. https://doi.org/10.1080/0284186X.2020.1843190.

31. Talens A, Guilabert M, Lumbreras B, Aznar MT, López-Pintor E. Medication Experience and Adherence to Oral Chemotherapy: A Qualitative Study of Patients’ and Health Professionals’ Perspectives. Int J Environ Res Public Health. 2021;18(8):4266. https://doi.org/10.3390/ijerph18084266.

32. Dowling M, Hunter A, Biesty L, Meskell P, Conway A, O’Boyle G et al. Driving and Disabling Factors of Noncurative Oral Chemotherapy Adherence: A Qualitative Evidence Synthesis. Oncol Nurs Forum. 2019;46:16–28. https://doi.org/10.1188/19.ONF.16-28.

33. Janse S, Janssen E, Huwig T, Basu Roy U, Ferris A, Presley CJ et al. Line of therapy and patient preferences regarding lung cancer treatment: a discrete-choice experiment. Curr Med Res Opin. 2021;37:643–653. https://doi.org/10.1080/03007995.2021.1888707.

34. Skrabal Ross X, Gunn KM, Suppiah V, Patterson P, Olver I. A review of factors influencing non-adherence to oral antineoplastic drugs. Support Care Cancer. 2020;28:4043–4050. https://doi.org/10.1007/s00520-020-05469-y.

35. Cardoso E, Csajka C, Schneider MP, Widmer N. Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs. Clin Pharmacokinet. 2018;57:1–6. https://doi.org/10.1007/s40262-017-0571-z.

36. Santoleri F, Lasala R, Ranucci E, La Barba G, Di Lorenzo R, Vetrò A et al. Medication Adherence to Tyrosine Kinase Inhibitors: 2-Year Analysis of Medication Adherence to Imatinib Treatment for Chronic Myeloid Leukemia and Correlation with the Depth of Molecular Response. Acta Haematol. 2016;136:45–51. https://doi.org/10.1159/000444626.

37. Boons CCLM, Timmers L, Janssen JJWM, Westerweel PE, Blijlevens NMA, Smit WM et al. Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib. Eur J Clin Pharmacol. 2020;76:1213–1226. https://doi.org/10.1007/s00228-020-02910-3.

38. Lasala R, Santoleri F. Association between adherence to oral therapies in cancer patients and clinical outcome: A systematic review of the literature. Br J Clin Pharmacol. 2022;88:1999–2018. https://doi.org/10.1111/bcp.15147.

39. Аль-Ради ЛС, Виноградова ОЮ, Кузьмина ЛА, Ломаиа ЕГ, Мартынкевич ИС, Морозова ЕВ и др. Хронический миелоидный лейкоз: клинические рекомендации. 2022. Режим доступа: https://oncology-association.ru/wp-content/uploads/2022/04/hronicheskij-mieloidnyj-lejkoz.pdf.

40. Inotai A, Ágh T, Maris R, Erdősi D, Kovács S, Kaló Z et al. Systematic review of real-world studies evaluating the impact of medication non-adherence to endocrine therapies on hard clinical endpoints in patients with non-metastatic breast cancer. Cancer Treat Rev. 2021;100(10159):102264. https://doi.org/10.1016/j.ctrv.2021.102264.

41. Walsh CA, Cahir C, Tecklenborg S, Byrne C, Culbertson MA, Bennett KE. The association between medication non-adherence and adverse health out-comes in ageing populations: A systematic review and meta-analysis. Br J Clin Pharmacol. 2019;85:2464–2478. https://doi.org/10.1111/bcp.14075.

42. Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open. 2018;8:e016982. https://doi.org/10.1136/bmjopen-2017-016982.

43. Murphy M, Bennett K, Ryan S, Hughes CM, Lavan AH, Cadogan CA. A systematic scoping review of interventions to optimise medication prescribing and adherence in older adults with cancer. Res Social Adm Pharm. 2022;18:2392–2402. https://doi.org/10.1016/j.sapharm.2021.04.011.

44. Talens A, López-Pintor E, Bejerano M, Guilabert M, Aznar MT, Aznar-Lou I et al. Influence of the COVID-19 Pandemic on Adherence to Orally Administered Antineoplastics. J Clin Med. 2022;11(9):2436. https://doi.org/10.3390/jcm11092436.

45. Cheli S, Lam WWT, Estapé T, Winterling J, Bahcivan O, Andritsch E et al. Risk perception, treatment adherence, and personality during COVID-19 pandemic: An international study on cancer patients. Psychooncology. 2022;31(1):46–53. https://doi.org/10.1002/pon.5775.